Evidence map›Paper›PMID 40573314›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

TrypPROTACs Unlocking New Therapeutic Strategies for Chagas Disease.

Ana Luísa Rodriguez Gini, Pamela Souza Tada da Cunha, Emílio Emílio João, Chung Man Chin, Jean Leandro Dos Santos, Esteban Carlos Serra, Cauê Benito Scarim

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. ACS omega · 2026
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ana Luísa Rodriguez GiniDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0003-2643-810X
Pamela Souza Tada da CunhaDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-3019-5393
Emílio Emílio JoãoDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0003-4134-9383
Chung Man ChinDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.
Jean Leandro Dos SantosDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-2460-2829
Esteban Carlos SerraFacultad de Ciencias Bioquímicas y Farmacéuticas, Universidad Nacional de Rosario, Rosario S2000CGK, Argentina.ORCID 0000-0001-5986-7459
Cauê Benito ScarimDepartment of Drugs and Medicines, School of Pharmaceutical Sciences, Sao Paulo State University (UNESP), Araraquara 14800-903, SP, Brazil.ORCID 0000-0002-2540-6395

Funding

Fundação de Amparo à Pesquisa do Estado de São Paulo 2023/05739-6Fundação de Amparo à Pesquisa do Estado de São Paulo 2024/05739-6National Council for Scientific and Technological Development 302689/2020-6
6 · The paper itself

Abstract

Chagas disease, caused by the protozoan parasite

Indexed as

drug designdrug targetingneglected tropical diseasesproteolysis targeting chimerasTrypanosoma cruzi infectionubiquitination

Identifiers

PMID40573314
PMCPMC12196504

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.